ES2107280T3 - Sales de nefazodona que tienen velocidades de disolucion mejoradas. - Google Patents

Sales de nefazodona que tienen velocidades de disolucion mejoradas.

Info

Publication number
ES2107280T3
ES2107280T3 ES95307812T ES95307812T ES2107280T3 ES 2107280 T3 ES2107280 T3 ES 2107280T3 ES 95307812 T ES95307812 T ES 95307812T ES 95307812 T ES95307812 T ES 95307812T ES 2107280 T3 ES2107280 T3 ES 2107280T3
Authority
ES
Spain
Prior art keywords
salts
nefazodone
improved dissolution
dissolution
dissolution speeds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95307812T
Other languages
English (en)
Inventor
Hemant N Joshi
Terry D Wilson
Jatin M Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2107280T3 publication Critical patent/ES2107280T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LAS SALES DE NEFAZODONA L-MALATA, L-TARTRATA Y METANO SULFONADAS MUESTRAN UNA DISOLUCION INTRINSECA AL AGUA Y UN REACTIVO COMPENSADOR THAM SIGNIFICATIVAMENTE MAS ALTO COMPARADO CON OTRAS SALES DE NEFAZODONA. LOS INDICES DE DISOLUCION MAS RAPIDOS DE ESTAS SALES A PH''S MAS ELEVADOS PUEDE SUGERIR MEJOR DISOLUCION Y ABSORCION EN EL INTESTINO, Y UNA BIODISPONIBILIDAD MEJORADA PARA FORMULACIONES ORALES.
ES95307812T 1994-11-02 1995-11-01 Sales de nefazodona que tienen velocidades de disolucion mejoradas. Expired - Lifetime ES2107280T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33339094A 1994-11-02 1994-11-02

Publications (1)

Publication Number Publication Date
ES2107280T3 true ES2107280T3 (es) 1997-11-16

Family

ID=23302579

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95307812T Expired - Lifetime ES2107280T3 (es) 1994-11-02 1995-11-01 Sales de nefazodona que tienen velocidades de disolucion mejoradas.

Country Status (10)

Country Link
US (1) US6034085A (es)
EP (1) EP0710653B1 (es)
JP (1) JPH08208480A (es)
AT (1) ATE157659T1 (es)
AU (1) AU689645B2 (es)
CA (1) CA2160423A1 (es)
DE (1) DE69500652T2 (es)
DK (1) DK0710653T3 (es)
ES (1) ES2107280T3 (es)
GR (1) GR3025376T3 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
DK1071425T3 (da) * 1998-04-24 2007-12-27 Scarista Ltd Behandling af depression og farmaceutiske præparater dertil
ES2152860B1 (es) * 1998-10-23 2001-08-16 Finaf 92 Sa Forma cristalina de la nefazodona y procedimiento para su preparacion.
DE69930952T2 (de) * 1998-11-02 2006-08-31 Alza Corp., Mountain View Verfahren und Vorrichtung zur kontrollierten Abgabe pharmazeutischer Mittel sowie Dosierungsform hierfür
US7407770B2 (en) * 2001-01-18 2008-08-05 Idexx Corporation Compositions and methods for detection of Ehrlichia canis and Ehrlichia chaffeensis antibodies
US20030129680A1 (en) * 2001-10-31 2003-07-10 O'connor Thomas Patrick Multi-analyte assay device
US20030194756A1 (en) 2002-04-12 2003-10-16 O'connor Thomas Patrick Peptides for detection of antibody to Ehrlichia equi
US7087372B2 (en) * 2001-01-18 2006-08-08 Idexx Laboratories, Inc. Compositions and methods for detection of Ehrlichia canis and Ehrlichia chaffeensis antibodies
US7183060B2 (en) * 2005-02-22 2007-02-27 Idexx Laboratories, Inc. Peptides for detection of antibody to Ehrlichia ewingii
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
WO2005065319A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
AU2004311879B2 (en) * 2003-12-31 2010-08-05 Cima Labs Inc. Effervescent oral opiate dosage form
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US7507789B2 (en) * 2007-04-09 2009-03-24 Idexx Laboratories, Inc. Detection of Anaplasma platys
EP2203469A4 (en) * 2007-09-21 2011-08-24 Idexx Lab Inc METHOD AND COMPOSITIONS FOR IDENTIFYING EHRLICHIA CHAFFEENSIS (P120)
WO2009039414A2 (en) * 2007-09-21 2009-03-26 Idexx Laboratories, Inc. Methods and compositions for detection of ehrlichia chaffeensis (vlpt)
WO2009070507A2 (en) * 2007-11-27 2009-06-04 Idexx Laboratories, Inc. Anaplasma phagocytophilum (aph) antigens and antibodies specific for anaplasma
CA2739796C (en) 2008-10-08 2018-11-06 Idexx Laboratories, Inc. Compositions and methods for detection of antibodies specific for anaplasma phagocytophilum (aph) and anaplasma platys (apl)
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
US9133525B2 (en) 2012-01-26 2015-09-15 Luc Montagnier Detection of DNA sequences as risk factors for HIV infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US4338317A (en) * 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
IT1196429B (it) * 1986-07-01 1988-11-16 Mediolanum Farmaceutici Srl Processo per la preparazione di pirido benzotiazine ad attivita' antibatterica e loro sali con acidi solfonici
US5188836A (en) * 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
TW279864B (es) * 1993-02-19 1996-07-01 Janssen Pharmaceutica Nv

Also Published As

Publication number Publication date
AU3458395A (en) 1996-05-09
EP0710653A1 (en) 1996-05-08
US6034085A (en) 2000-03-07
GR3025376T3 (en) 1998-02-27
DE69500652D1 (de) 1997-10-09
JPH08208480A (ja) 1996-08-13
CA2160423A1 (en) 1996-05-03
EP0710653B1 (en) 1997-09-03
AU689645B2 (en) 1998-04-02
DE69500652T2 (de) 1998-02-19
DK0710653T3 (da) 1997-12-08
ATE157659T1 (de) 1997-09-15

Similar Documents

Publication Publication Date Title
ES2107280T3 (es) Sales de nefazodona que tienen velocidades de disolucion mejoradas.
AR064896A2 (es) Composicion farmaceutica no higroscopica
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
ATE395916T1 (de) Orale methylphenidat-formulierungen mit kontrollierter/veränderter freisetzung
ES2188584T3 (es) Derivados heterociclicos de amina.
SE9503143D0 (sv) New preparation
FI931250A0 (fi) Sulfonamido- och sulfonamidokarbonyl-pyridin-2-karboxylsyraamider och deras pyridin-n-oxider, foerfarande foer deras framstaellning och deras anvaendning som laekemedel
CR6530A (es) Metodo para inhibir la agregacion de proteinas amiloidesy formacion de imagenes de depositos amiloides utilizando derivados de isoindolina
DK0439030T3 (da) Orale lægemiddelformer af pimobendan
ES2176296T3 (es) Composiciones farmaceuticas que permiten la liberacion prolongada de trimetacidina despues de la administracion por via oral.
ATE157080T1 (de) Ethanolaminderivate mit anti-pollakiurawirkung
ITRM950480A0 (it) Metodo per aumentare la rapidita' di allevamento di neonati mediante impiego di mangime per scrofe da riproduzione.
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
FR2754177B1 (fr) Microspheres pharmaceutiques d'acide valproique pour administration orale
AR025638A1 (es) Conjugados de glucopiranosidas de 2-(4-hidroxi-fenil)-3-metil-1-/4-(2-amin-1-il-etoxi)-bencil/-1h-indol-5-oles
BR9205827A (pt) Composições farmacêuticas ingeriveis para tratamento de distúrbios do trato gastrintestinal superior
FR2678836B1 (fr) Formulations pour voie orale d'ubidecarenone sous la forme de solutions aqueuses.
DE69617868D1 (de) Geschmacksmaskierte wässrige Lösungen enthaltend Ibuprofen und Menthol
ITMI920203A1 (it) Canna da pesca, in particolare per l'impiego nella pesca in acque montane o torrenti.
FR2794967B1 (fr) Ogive dilatatrice introduite entre des surfaces osseuses articulaires concaves pour en restaurer l'ecartement et la position angulaire
BR9907195A (pt) " formulações de tiagabina de liberação prolongada com efeitos colaterais reduzidos "
FR2798279B1 (fr) Dispositif d'insemination artificielle, notamment pour la reproduction des porcs
FR2702960B1 (fr) Leurre pour l'administration orale de médicaments vétérinaires.
KR970000226A (ko) S-이부프로펜의 경구용 제형
FR2847457B3 (fr) Dispositif permettant de corriger le retrecissement valvulaire cardiaque chez l'homme

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 710653

Country of ref document: ES